Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study

BACKGROUND: Immunoglobulin therapy has become a major treatment option in several autoimmune neuromuscular disorders. For patients with Myasthenia Gravis (MG), intravenous immunoglobulin (IVIg) has been used for both crisis and chronic management. Subcutaneous Immunoglobulins (SCIg), which offer the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourque, P. R., Pringle, C. E., Cameron, W., Cowan, J., Chardon, J. Warman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973986/
https://www.ncbi.nlm.nih.gov/pubmed/27490101
http://dx.doi.org/10.1371/journal.pone.0159993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973986/
https://www.ncbi.nlm.nih.gov/pubmed/27490101
http://dx.doi.org/10.1371/journal.pone.0159993

Ejemplares similares